About Sam Barnum

This author has not yet filled in any details.
So far Sam Barnum has created 30 blog entries.

An Overview of Digital Health in China

2020-05-06T13:19:09-04:00

We recently discussed the challenges and opportunities for diagnostic players amidst and post- the COVID-19 chaos in the context of China’s health care system. In this issue, we will discuss another industry sector that may benefit from this global pandemic, digital health.

An Overview of Digital Health in China2020-05-06T13:19:09-04:00

Boston Healthcare’s Webinar Library

2020-05-19T12:57:35-04:00

Browse a variety of recent webinars presented by the team at Boston Healthcare Associates. We will regularly update this library of free life science webinars as we continue to produce them throughout 2020.

Boston Healthcare’s Webinar Library2020-05-19T12:57:35-04:00

FDA Releases Final Guidance on Oncology Therapeutic Class Labeling of Companion Diagnostics

2020-04-21T17:02:39-04:00

The Food and Drug Administration recently published final guidance entitled “Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products,” in which the FDA lists several key considerations for companion diagnostic manufacturers.

FDA Releases Final Guidance on Oncology Therapeutic Class Labeling of Companion Diagnostics2020-04-21T17:02:39-04:00

The VALID and VITAL Acts: What Do They Mean for Diagnostic Innovators?

2020-04-06T15:19:56-04:00

At its core, the VALID Act would explicitly grant the FDA authority to regulate LDTs through a risk-based framework that categorizes LDTs as high risk or low risk, with high-risk tests facing approval requirements that are comparable to existing medical device regulations.

The VALID and VITAL Acts: What Do They Mean for Diagnostic Innovators?2020-04-06T15:19:56-04:00

China Social Health Insurance Fund Annual Spending – Insights from 2018 Statistics

2020-02-04T17:23:36-05:00

An official statistical report of the 2018 national social health insurance fund, which provides high-level data for an outsider to try to grasp the essential characteristics of China’s healthcare funding and delivery system and understand the challenges an industry player as well as the Chinese government payer are facing...

China Social Health Insurance Fund Annual Spending – Insights from 2018 Statistics2020-02-04T17:23:36-05:00

Navigating the Italian HTA Process: Essentials to a Favorable Review

2020-01-16T13:37:20-05:00

From November 1, 2016 to September 1, 2019, the Italian Medicines Agency, AIFA evaluated a total of 166 Dossiers - 28 were related to orphan drugs, 56 to new active substances, 57 to extensions of indications for drugs already reimbursed, and 25 to other types of negotiations.

Navigating the Italian HTA Process: Essentials to a Favorable Review2020-01-16T13:37:20-05:00